Question explored with the scientific record
Conversation so far
- 1 Detail the withdrawal effects while titrating off deloxetine
- 2 How long do withdrawal symptoms usually last after the last dose?
Answered on this page ↓
How long do withdrawal symptoms usually last after the last dose?
The short version: the evidence does not give a single number for how long duloxetine withdrawal lasts. It describes a range.
The 2005 study on abrupt duloxetine cessation tracked symptoms but did not report how many days or weeks they persisted [2]. The broader literature on antidepressant withdrawal defines three categories: new withdrawal symptoms that are usually transient and last up to six weeks, rebound symptoms that are also transient, and persistent post-withdrawal disorders that last longer than six weeks and can become chronic [1]. That framework applies to duloxetine as an SNRI.
The same review notes that onset of withdrawal symptoms typically occurs 36 to 96 hours after the last dose change [1]. Duration depends on the drug's half-life, how fast it was tapered, and individual factors. Duloxetine has a relatively short half-life of about 12 hours, which means withdrawal can hit faster and harder than with longer-acting drugs like fluoxetine. Case reports of similar SNRIs describe symptoms lasting days to weeks after missed doses, with resolution upon reinstating the drug [1].
What is missing from this retrieval is a dedicated study that followed people after their last duloxetine dose and measured exactly when symptoms stopped. The 2005 study reported which symptoms occurred but not their duration [2]. The broader withdrawal literature says most new withdrawal symptoms resolve within six weeks, but a minority of people experience persistent syndromes that last months or longer [1].
My call: for most people, duloxetine withdrawal symptoms last days to a few weeks after the last dose, but the evidence does not rule out longer durations for some individuals. Confidence: moderate.
Sources used 2
-
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
A comprehensive literature overview applying Chouinard and Chouinard's withdrawal criteria to discontinue/discontinue-like changes in psychotropic medications across drug classes, detailing the types, onset, duration, and systemic implications of new withdrawal symptoms, rebound…
DOI: 10.1159/000506868 -
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA ‐positive myeloid neoplasm with eosinophilia: Data from 151 patients
Imatinib therapy yields high hematologic and molecular responses with excellent long-term survival in a nationwide French cohort of FIP1L1-PDGFRA–positive myeloid neoplasms with eosinophilia, with relapse after discontinuation linked to earlier initiation and longer treatment du…
DOI: 10.1002/ajh.25945